ACAD
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson\'s, Alzheimer\'s and schizophrenia.
Acadia Pharmaceuticals Inc. (ACAD) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (F). The rating has held at C for 4 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B- (3.1) | C (2.4) | B (3.5) | C- (2.0) | F (0.0) | C (2.2) |
| 2026-11-10 | B- (3.1) | C (2.4) | B (3.5) | C- (1.9) | F (0.0) | C (2.2) |
| 2026-11-03 | C+ (2.8) | C+ (2.7) | B (3.5) | C (2.2) | F (0.0) | C (2.2) |
| 2026-10-27 | B- (2.9) | C+ (2.6) | B (3.5) | C- (2.1) | F (0.0) | C (2.2) |
| 2026-10-20 | B- (2.9) | C+ (2.6) | B (3.5) | C+ (2.8) | F (0.0) | C (2.4) |